Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about GILEAD SCIENCES, INC.
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
AQ
07/20ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
MT
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
DJ
07/19ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
DJ
07/19Health Care Down Amid Defensive Bias -- Health Care Roundup
DJ
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
MT
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
07/19BIONTECH : to Buy Neoantigen TCR Cell Therapy Platform, Facility from Gilead's K..
MT
07/19BioNTech strengthens cancer therapy expertise with U.S. acquisition
RE
07/19PRESS RELEASE : BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platf..
DJ
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
07/17GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
BU
07/17GILEAD SCIENCES : Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate Hig..
BU
07/17Gilead Sciences, Inc Announces New Results from the Ongoing Phase 2/3 CAPELLA..
CI
07/17Gilead Sciences, Inc Announces Four-Year Biktarvy® Data Presented At Ias 2021..
CI
07/15GILEAD SCIENCES : to Release Second Quarter 2021 Financial Results on Thursday, ..
BU
07/13GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
AQ
07/12GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
BU
07/08GILEAD SCIENCES : RBC Capital Adjusts Gilead Sciences PT to $81 From $82 Expecti..
MT
07/07COUNTRYSIDE PROPERTIES : UK's Countryside to focus solely on Partnerships busine..
RE
07/05READY, SET, GO : Crystalize Your Thinking
AQ
07/02GILEAD SCIENCES : Response to Open Letter Regarding Access to AmBisome® (liposom..
PU
06/29GILEAD SCIENCES : Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free..
AQ
06/29EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
RE
06/29FS DEVELOPMENT II : Blank-Check Firm FS Development II to Merge With Pardes Bios..
MT
06/29BERGENBIO : COVID-19 Drug Cuts Death In Mid-Stage Studies
MT
06/29Pardes Biosciences, Inc. announced that it expects to receive $75 million in ..
CI
06/28GILEAD SCIENCES : Seeks FDA Nod for Lenacapavir for HIV-1 Patients
MT
06/28GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
BU
06/28Gilead Sciences, Inc. Submits New Drug Application to U.S. Food and Drug Admi..
CI
06/28GILEAD SCIENCES' : Kite Arm Says Yescarta Improves Event-Free Survival by 60% in..
MT
06/28Gilead Submits NDA for Lenacapavir to U.S. FDA
DJ
06/28GILEAD SCIENCES : Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Fre..
BU
06/27LUPIN : Launches HIV-1 Infection Treatment Drug in US
MT
06/25GILEAD SCIENCES : Treatment with Hepcludex Was Shown to Achieve Significant Resp..
AQ
06/25PRESS RELEASE : Roche's Actemra/RoActemra receives -2-
DJ
06/25PRESS RELEASE : Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Author..
DJ
06/24U.S. approves Roche drug for emergency use against severe COVID-19
RE
06/24GILEAD SCIENCES : Provides Positive Update on Safety, Efficacy of Hepatitis Drug
MT
06/24GILEAD SCIENCES : Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve S..
BU
06/24Gilead Sciences, Inc. Announces Interim Results from the Phase 2B and Phase 3..
CI
06/24Gilead Sciences Sees Positive Results From Trial for Hepatitis Treatment
DJ
06/23SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma JV Secures CAR T-Cell Therapy Appro..
MT
06/23GILEAD SCIENCES : Unauthorized COVID-19 drugs bound for Mexico seized by U.S. au..
RE
06/23GILEAD SCIENCES : Unit JV Wins China Regulatory Ok for CAR T-Cell Therapy
MT
06/23GILEAD SCIENCES : Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell T..
BU
06/23MARKET CHATTER : Federal Authorities Capture Unauthorized Versions of Gilead Sci..
MT
06/23EUROPEAN MIDDAY BRIEFING : Stocks Slip as PMI -2-
DJ
06/23NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
06/23MASTERCARD FOUNDATION : Robin Washington nommé au Conseil d'Administration par l..
DJ
06/23Lyndra Therapeutics, Inc. announced that it has received $60.5 million in fun..
CI
06/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Nod to Market Lymphoma Drug in..
MT
06/22SHANGHAI FOSUN PHARMACEUTICAL : Chinese regulator approves first CAR-T cell ther..
RE
06/22GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease P..
AQ
06/22GILEAD SCIENCES : Veklury Associated With a Reduction in Mortality Rate in Hospi..
AQ
06/22Mastercard Foundation Appoints Robin Washington to Board of Directors
DJ
06/21GILEAD SCIENCES : Says Veklury Lowers Mortality Rate in COVID-19 Treatment
MT
06/21GILEAD SCIENCES : remdesivir reduces COVID-19 mortality risk- data
RE
06/21GILEAD SCIENCES : Statement on New England Journal of Medicine Publication of Po..
AQ
06/21GILEAD SCIENCES : Veklury® (Remdesivir) Associated With a Reduction in Mortality..
BU
06/21Gilead Sciences, Inc.’s Veklury® Associated with A Reduction in Mortality Rat..
CI
06/21GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease P..
BU
06/17GILEAD SCIENCES : Kite Partners With Shoreline Biosciences to Develop Cancer The..
MT
06/17GILEAD SCIENCES : Kite and Shoreline Biosciences Enter Into Strategic Partnershi..
BU
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICS : Set for $25 Million Milestone Payment from Gilead After In..
MT
06/15GILEAD SCIENCES : Jounce Therapeutics Achieves First Milestone in Exclusive Lice..
AQ
06/15Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement w..
CI
06/15Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
DJ
06/14INSIDER TRENDS : Gilead Sciences Insider Converts Option/Derivative Security to ..
MT
06/14GILEAD SCIENCES : University of Cambridge - Longer-term Data for Kite's Yescarta..
AQ
06/14GILEAD SCIENCES' : Lymphatic System Cancer Drug Shows 94% Response Rate in Follo..
MT
1  2  3  4  5  6  7  8  9  10Next
Official Publications
06/15Report 
06/10Report 
05/12Report 
05/12SEC Filing 8K 
05/06SEC Filing 10Q-1 
05/06Report 
Upcoming event on GILEAD SCIENCES, INC.